Watch hVIVO’s July 2024 Capital Markets Day here
At hVIVO, we play an important role in improving global health by supporting the clinical development of medicinal products, especially infectious and respiratory disease products, through human challenge trials. As a growing organization, we recognise the importance of continually improving our governance and prioritising social and environmental concerns in all our work.
We are committed to operating as a responsible business; and as part of this commitment, we are currently assessing the Company’s environmental, social and governance protocols and policies. hVIVO has established a cross business working group, called the ESG Group, which focuses on identifying risks and opportunities related to climate change and other social and governance topics. Yamin ‘Mo’ Khan leads the ESG Group and report directly to the Audit and Risk Committee. The ESG Group consists of representatives from various areas of our business and report to the to Audit and Risk Committee, which is responsible for reviewing the Company’s ESG reporting and recommending it to the Board.
Infectious diseases are a significant burden to global health, and hVIVO plays an important role in helping to bring vital vaccines & antivirals to the market faster than otherwise possible, using human clinical trials.
Our employees are the key to our success; in line with our Diversity & Equal Opportunities Policy, we are focussed on building a strong corporate culture, with diversity and equality at the centre.
We place participants and patients at the heart of our business and carefully safeguard their wellbeing in clinical research and data protection and ensure that their feedback is heard so that we can continually improve our processes.
We believe in giving back to our community and those in need. To achieve this goal, we have implemented numerous new initiatives hVIVO’s Volunteering Policy and work towards the implementation of new initiatives such as our Charitable Donations Policy and Community Engagement Programme.
We are committed to reducing our impact on the environment; as part of our Environmental Policy, we ensure all energy consumption is monitored and are working towards implementing measurable metrics and targets to help minimise our carbon footprint.
We operate our trials in the highest quality safety, regulatory and ethical environment. We are committed to honesty, transparency and quality which is embedded in our Clinical Governance Policy and Business Code of Ethics.
Yamin 'Mo' Khan
CEO & Head of the ESG Group
“At hVIVO, we have a clear vision: to transform global healthcare by revolutionising the drug development process through scientific ingenuity. This vision has sustainability, ethical governance, and social responsibility embedded into every aspect of our operations. As we continue to Optimise, Scale, and Diversify the business, our commitment to ESG principles plays a key role in our decision-making.
In 2024, we made significant strides in delivering on our vision. The launch of our state-of-the-art facility in Canary Wharf has strengthened our ability to conduct more studies with increased efficiency, and with expanded service offerings, supporting a growing number of biopharma clients in their mission to address unmet medical needs. We broadened our range of human challenge models in 2024, and with the addition of CL-3 capabilities, we can provide our world leading HCTs to support drug development in more disease indications than ever before. I am proud that we successfully achieved an Ecovadis sustainability rating in 2024.
An important milestone in 2024 was achieving ISO 14001 accreditation for our new Canary Wharf site, with plans to expand this across our other sites in the years ahead. Energy-efficient air handling systems, waste reduction initiatives, and responsible food sourcing are just some of the steps we have taken to ensure environmentally responsible operations. As we grow, we will continue to invest in renewable energy solutions and sustainable infrastructure.
Our team is the driving force behind our success. We remain focused on cultivating an inclusive and open working environment across the Group, supported by our policies, initiatives, and events. With the acquisition of CRS Mannheim, CRS Kiel, and Cryostore in 2025, we look forward to bringing our collaborative culture and ESG focus to these new subsidiaries.
Through our Volunteer Leave Policy and charitable donation initiatives, we empower employees to give back to the communities in which we operate. In 2024, we expanded our partnerships with local charities and have exciting plans for the year ahead to expand these initiatives further to give back to the community and support the next generation of scientists.
hVIVO is at the forefront of scientific innovation, but our success is defined by more than just financial success. It is measured by our ability to operate responsibly, ethically, and sustainably while driving meaningful change in global healthcare. I would like to sincerely thank our employees, trial participants, and partners for their dedication to scientific research. Together, we can deliver on our vision to transform global healthcare by revolutionising the drug development through scientific ingenuity.”
